News
-
-
PRESS RELEASE
Moderna Announces mNEXSPIKE Generates Strong Immune Response Against LP.8.1 Variant in Humans
Moderna's 2025-2026 mNEXSPIKE formula shows significant increase in LP.8.1-neutralizing antibodies, demonstrating strong immune responses against COVID-19 strains. Preliminary immunogenicity data supports the efficacy and safety of the vaccine -
-
-
-
-
-
PRESS RELEASE
Moderna Announces First Made-in-Canada mRNA Vaccines Delivered to Canadian Provinces and Territories
Moderna ships first made-in-Canada mRNA vaccines, advancing domestic production capacity and national health security. Updates on Canada's COVID-19 public vaccination program and regulatory approvals -
-